All In Biotech

Drug Trial Radar · NCT05422482

A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ

An Open-Label, Phase 1 and Extension Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ Who Have Central Nervous System Involvement and Are Receiving Treatment with Intravenous Drug

Last checked: Nov 20, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Sep 20, 2022

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Jun 16, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 months, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intracerebroventricular GC1123 in patients with MPS Ⅱ who have central nervous system involvement and are receiving treatment with intravenous drug

Conditions

  • Mucopolysaccharidosis II
  • Hunter Syndrome

Interventions

  • GC1123Biological

    ICV-administered Hunterase, Idursulfase-ß

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and frequency of serious adverse events (SAEs)Time frame: Every 28 days from Week 1 through study completion (about 110 weeks)
  2. Frequency and characteristics (severity, outcome, etc.) of adverse eventsTime frame: Every 28 days from Week 1 through study completion (about 110 weeks)
  3. Presence of clinically significant abnormal echocardiography resultsTime frame: Week 1 to Phase I study completion (about 26 weeks)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Pusan National University Yangsan Hospital

    Pusan, South Korea

  • Seoul National University

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.